TechNavio today launched its report Global Central Nervous System Drugs Market 2011-2015 based on an in-depth study covering the Americas, and the EMEA and APAC regions. The report aims to aid decision makers’ understanding of the significant trends impacting this market.
Commenting on the report, an analyst from TechNavio’s Healthcare team said; ”The launch of novel molecules is expected to fulfill unmet needs and drive the growth of the Global Central Nervous System (CNS) Drugs market in the coming years. For instance, many orally administered novel molecules are in the pipeline for multiple sclerosis. Also, in the case of Alzheimer™s disease there are products in the pipeline that include novel molecules which target the underlying causes of the disease and thus offer clinical benefits to patients.”
According to the report, the probability of occurrence of mental disorders increases with age and thus the increasing size of the aging population drives the growth of the Global CNS Drugs market.
Further, the report also discusses that one of the most important challenges in the market is the patent expiration of some of the key CNS drugs.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key players.
TechNavio, the market research platform of Infiniti Research Ltd, publishes periodic reports on niche and emerging technologies. For further information, please visit http://goo.gl/emzId
Follow us on Twitter @ Technavio
TechNavio Announces the Publication of its Report – Global Central Nervous System Drugs Market 2011-2015
